Swiss contract development and manufacturing organization (CDMO) Lonza has cut around 200 jobs at a manufacturing facility in California, USA.
The site is focused on the production of various components of biologic manufacturing, with news of the staff reductions coming through a government website set up for this purpose.
Another biotech company, Dewpoint Therapeutics, has also laid off around 15% of its staff, around 20 people, an update on the website shows.
Dewpoint is focused on developing biomolecular condensates, and is making the layoffs as part of an operational reorganization.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze